Introduction
Drug associated muscle adverse reaction (DAMAR) refers to damage of muscle tissues and cells associated with drugs, includes myalgia, myopathy, myositis, myonecrosis and rhabdomyolysis[1]. The serious adverse reaction, rhabdomyolysis, can cause acute renal failure or electrolyte disorders[2,3], therefore the monitoring of DAMAR is an important composition of drug safety evaluation. DAMAR exists widely among statins [4], often called statin associated muscle symptoms (SAMS), the clinical features of which had been focused and studied, leading to modification of drug labels[5]. Many kinds of drugs can cause DAMAR besides statins with plenty of case reports [6,7] but lacking in research of clinical features and incidence.
In this study, we performed real world safety evaluation using muscle adverse reaction module[8] in adverse drug event active surveillance and assessment system-Ⅱ (ADE-ASAS-Ⅱ)[9]. To provide references to clinical practice, we retrospectively analysis incidence, clinical features, and associated drugs of DAMAR.